Novocure’s Optune Pax FDA Approval Boosts Pancreatic Cancer Survival by Two Months
FDA approved Optune Pax, a portable non-invasive device by Novocure that delivers tumor treating fields for locally advanced pancreatic cancer under Breakthrough Device designation. PANOVA-3 trial showed 16.2-month median overall survival versus 14.2 months with chemotherapy alone, a two-month improvement and extended pain progression.
1. FDA Approval of Optune Pax
FDA approved Optune Pax on Feb. 11 as the first new treatment for locally advanced pancreatic cancer in nearly 30 years. The portable, non-invasive system carries Breakthrough Device designation and delivers alternating electric fields designed to disrupt tumor cell division.
2. Clinical Trial Results
The PANOVA-3 Phase 3 trial enrolled 571 patients, pairing Optune Pax with standard chemotherapy. The combination achieved a median overall survival of 16.2 months versus 14.2 months for chemotherapy alone, extended time to pain progression, and was associated with mostly mild skin reactions.
3. Stock Price Reaction
NovoCure shares surged almost 30% in after-hours trading following the approval announcement. The stock opened at $14.79 the next day, dipped to $13.38 on profit taking, then rebounded to $13.40 as investors assessed growth prospects.
4. Analyst Ratings and Outlook
HC Wainwright maintained a Buy rating and raised its target price to $47, while Wedbush set a Neutral rating with an $18 target and JP Morgan held Neutral at $23. These actions reflect confidence in long-term potential tempered by market adoption uncertainties.